23andMe Launches New Genetic Report on Osteoporosis
31 janv. 2025 07h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human...
23andMe Special Committee Announces Exploration of Strategic Alternatives
28 janv. 2025 17h25 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- The Special Committee of the Board of Directors of 23andMe Holding Co. (Nasdaq: ME) (“23andMe” or the “Company”), a leading human genetics...
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
28 janv. 2025 17h15 HE
|
23andMe, Inc.
Company Notes Continued Concerns Regarding Liquidity and Consideration of Potential Ways to Address Operational and Financial Challenges SUNNYVALE, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- 23andMe...
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit’s Trusted Technology
08 janv. 2025 07h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif. and LONDON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics company, today announced the launch of Discover23®, a new research offering...
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation
20 nov. 2024 07h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a...
23andMe Reports Second Quarter Fiscal Year 2025 Financial Results
12 nov. 2024 07h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, reported its financial results for the second quarter...
23andMe Announces Business Restructuring to Streamline Operations, Reduce Costs and Position Company for the Future
11 nov. 2024 17h30 HE
|
23andMe, Inc.
Reduces workforce by roughly 40%; expects annualized cost savings of more than $35 million Discontinues development of therapeutics division and commences strategic alternatives process for all...
CORRECTION - 23andMe to Report Q2 FY2025 Financial Results
07 nov. 2024 17h54 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (Nasdaq: ME) (23andMe) will report financial results for the...
23andMe to Report Q2 FY2025 Financial Results
07 nov. 2024 07h30 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial...
23andMe Regains Compliance With Nasdaq Listing Requirements
30 oct. 2024 17h00 HE
|
23andMe, Inc.
SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced that the...